-
Efficacy Analysis of “T+A” Therapy in Different Treatment Populations of HCC
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Most patients are unable to undergo surgical resection at the time of diagnosis, making systemic therapy an important treatment approach for this group. The combination immunotherapy of Atezolizumab plus Bevacizumab (“T+A”) has become the new first-line standard treatment for unresectable HCC patients due…
-
Progress and considerations in the research of malnutrition in patients with cirrhosis
Malnutrition, a subacute or chronic nutritional condition, arises from insufficient (or excessive) food intake and/or inflammation, leading to compromised body composition and reduced bodily functions, adversely affecting clinical outcomes and prognosis. Given the liver’s central role in metabolizing glucose, proteins, and fats, patients with ongoing liver damage, especially cirrhosis, commonly suffer from malnutrition. Studies indicate…
-
Dr. Massimo Federico: 10-Year Follow-up Results of Early FDG-PET Adaptive Treatment for Limited-Stage HL
At the International Malignant Lymphoma Conference (ICML 2023), Dr. Massimo Federico from University of Modena and Reggio Emilia, presented a captivating report on 10-Year Follow-up Analysis of the EORTC/LYSA/FIL H10 Randomized Intergroup Trial during the “Focus on Hodgkin Lymphoma” session. Oncology Frontier specially invited Dr. Federico for an in-depth interview on this topic.
-
Dr. Xu Pengpeng: Preliminary Results of Targeted Drug Combination with CHOP as First-Line Treatment for PTCL
Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with poor prognosis. Standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy is the most widely used regimen for first-line treatment of PTCL.…
-
The clinical insights gained from T-cell receptor sequencing in revealing the immune characteristics of liver cancer staging
T lymphocytes play a crucial role in human adaptive immunity by recognizing antigens major histocompatibility complex (MHC) molecules through specific T-cell receptors (TCRs) on their surface. 95% of T cells have TCRs composed of α and β peptide chains connected by disulfide bonds, forming an α/β heterodimer. Each chain consists of constant and variable domains.…
-
Dr. Zhang Huilai Interpreted Multiple Studies by His Team at ICML 2023
Editor’s Note: The 17th International Conference on Malignant Lymphoma (ICML) took place from June 13 to 17, 2023, in Lugano, Switzerland. As the largest international conference in the field of…
-
APASL 2023 | Prof. Rao Huiying: Eliminating HCV, Key Issues That Still Need Attention
Chronic HCV infection is a global public health issue. With the widespread use of direct-acting antiviral agents (DAAs), chronic hepatitis C (CHC) has become a curable disease. However, after successful HCV clearance and achieving sustained virological response (SVR), do CHC patients still face risks of liver-related events? Currently, there is a significant gap in reaching…
-
APASL 2023 | Prof. George Lau: Seeking the “Cure” for Liver Disease – A Hepatologist’s Thirty-Year Journey of Exploration
The 32nd annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL) was held at the Taipei International Convention Center in Taiwan, China, from February 15 to 19, 2023. During the conference, the APASL Executive Committee awarded four prestigious honors, including the third APASL Highest Honor Award, the Okuda-Omata Outstanding Achievement Award,…
Connecting Medical Expertise through Media